Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - Implications for cancer therapies

Current Medicinal Chemistry

Volumn 19, Issue 12, 2012, Pages 1751-1764

  Frey, B ^a   Rubner, Y ^a   Wunderlich, R ^a   Weiss, E M ^a   Pockley, A G ^b,c   Fietkau, R ^a   Gaipl, U S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Abscopal effects; Anti tumor immunity; Cancer; Danger signals; Dendritic cells; Immune editing; Immunogenic tumor cell death; Radiotherapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA INTERFERON; CALRETICULIN; CASPASE 8; CD11B ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOUBLE STRANDED DNA; FAS LIGAND; GAMMA INTERFERON; GRANULYSIN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; INTERLEUKIN 18; LIPOCORTIN 4; LIPOCORTIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; OXALIPLATIN; PHOSPHATIDYLSERINE; PROTEIN P30; PROTEIN P54; PROTEIN S 100; REACTIVE OXYGEN METABOLITE; RECEPTOR INTERACTING PROTEIN 140; SCLEROPROTEIN; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CD4+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CLINICAL PRACTICE; COLONY FORMATION; DENDRITIC CELL; DISEASE COURSE; DISEASE SURVEILLANCE; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINT; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; INNATE IMMUNITY; IONIZING RADIATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NECROSIS; NONHUMAN; TH1 CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; X RAY;

ANIMALS; CELL DEATH; HUMANS; IMMUNE SYSTEM; IMMUNITY; MODELS, IMMUNOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; RADIATION, IONIZING; TUMOR MICROENVIRONMENT;

EID: 84860503128     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800099811     Document Type: Article

References (199)

1. Schreiber, R. D.; Old, L. J.; Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331, 1565-1570.
2. Steel, G. G. From targets to genes: a brief history of radiosensitivity. Phys Med Biol, 1996, 41, 205-222. (Pubitemid 26053204)
3. Hall, E. J. Radiobiology for the radiologist. 5 ed. Philadelphia: Lippincott Williams &-Wilkins, 2000.
4. Willers, H.; Held, K. D. Introduction to clinical radiation biology. Hematol Oncol Clin North Am, 2006, 20, 1-24.
5. Goodhead, D. T.; Thacker, J.; Cox, R. Weiss Lecture. Effects of radiations of different qualities on cells: molecular mechanisms of damage and repair. Int J Radiat Biol, 1993, 63, 543-556. (Pubitemid 23162759)
6. Willers, H.; Heilmann, H. P.; Beck-Bornholdt, H. P. [One hundred years of radiotherapy. Historical origins and development of fractionated irradiation in German speaking countries]. Strahlenther Onkol, 1998, 174, 53-63. (Pubitemid 28078959)
7. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444, 756-760. (Pubitemid 44949604)
8. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; El-Deiry, W. S.; Golstein, P.; Green, D. R.; Hengartner, M.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Malorni, W.; Nunez, G.; Peter, M. E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 2009, 16, 3-11.
9. Weiss, E. M.; Frey, B.; Rodel, F.; Herrmann, M.; Schlucker, E.; Voll, R. E.; Fietkau, R.; Gaipl, U. S. Ex vivo-and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann N Y Acad Sci, 2010, 1209, 109-117.
10. Bernier, J.; Hall, E. J.; Giaccia, A. Radiation oncology: a century of achievements. Nat Rev Cancer, 2004, 4, 737-747. (Pubitemid 39215072)
11. Morgan, W. F. Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat Res, 2003, 159, 567-580. (Pubitemid 36539236)
12. Mole, R. H. Whole body irradiation; radiobiology or medicine? Br J Radiol, 1953, 26, 234-241.
13. Ohba, K.; Omagari, K.; Nakamura, T.; Ikuno, N.; Saeki, S.; Matsuo, I.; Kinoshita, H.; Masuda, J.; Hazama, H.; Sakamoto, I.; Kohno, S. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut, 1998, 43, 575-577. (Pubitemid 28462047)
14. Sham, R. L. The abscopal effect and chronic lymphocytic leukemia. Am J Med, 1995, 98, 307-308.
15. Wersall, P. J.; Blomgren, H.; Pisa, P.; Lax, I.; Kalkner, K. M.; Svedman, C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol, 2006, 45, 493-497. (Pubitemid 43884622)
16. Azzam, E. I.; de Toledo, S. M.; Little, J. B. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc Natl Acad Sci U S A, 2001, 98, 473-478. (Pubitemid 32105066)
17. Sowa Resat, M. B.; Morgan, W. F. Radiation-induced genomic instability: a role for secreted soluble factors in communicating the radiation response to non-irradiated cells. J Cell Biochem, 2004, 92, 1013-1019. (Pubitemid 44264248)
18. Nobler, M. P. The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation. Radiology, 1969, 93, 410-412.
19. Demaria, S.; Ng, B.; Devitt, M. L.; Babb, J. S.; Kawashima, N.; Liebes, L.; Formenti, S. C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys, 2004, 58, 862-870. (Pubitemid 38221143)
20. Lugade, A. A.; Moran, J. P.; Gerber, S. A.; Rose, R. C.; Frelinger, J. G.; Lord, E. M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol, 2005, 174, 7516-7523. (Pubitemid 40806254)
21. Nikitina, E. Y.; Gabrilovich, D. I. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumorbearing mice: approach to treatment of advanced stage cancer. Int J Cancer, 2001, 94, 825-833. (Pubitemid 33032831)
22. Shiraishi, K.; Ishiwata, Y.; Nakagawa, K.; Yokochi, S.; Taruki, C.; Akuta, T.; Ohtomo, K.; Matsushima, K.; Tamatani, T.; Kanegasaki, S. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res, 2008, 14, 1159-1166. (Pubitemid 351302564)
23. Takeshima, T.; Chamoto, K.; Wakita, D.; Ohkuri, T.; Togashi, Y.; Shirato, H.; Kitamura, H.; Nishimura, T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res, 2010, 70, 2697-2706.
24. Dewan, M. Z.; Galloway, A. E.; Kawashima, N.; Dewyngaert, J. K.; Babb, J. S.; Formenti, S. C.; Demaria, S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res, 2009, 15, 5379-5388.
25. Camphausen, K.; Moses, M. A.; Menard, C.; Sproull, M.; Beecken, W. D.; Folkman, J.; O'Reilly, M. S. Radiation abscopal antitumor effect is mediated through p53. Cancer Res, 2003, 63, 1990-1993. (Pubitemid 36460868)
26. Dunn, G. P.; Bruce, A. T.; Ikeda, H.; Old, L. J.; Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 2002, 3, 991-998. (Pubitemid 35363648)
27. Smyth, M. J.; Hayakawa, Y.; Takeda, K.; Yagita, H. New aspects of naturalkillercell surveillance and therapy of cancer. Nat Rev Cancer, 2002, 2, 850-861. (Pubitemid 37328903)
28. Raulet, D. H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol, 2004, 5, 996-1002. (Pubitemid 41057716)
29. Lieberman, J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol, 2003, 3, 361-370. (Pubitemid 37323196)
30. Chan, C. W.; Housseau, F. The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ, 2008, 15, 58-69. (Pubitemid 350286173)
31. Matzinger, P. The danger model: a renewed sense of self. Science, 2002, 296, 301-305. (Pubitemid 34303674)
32. Janeway, C. A., Jr.; Medzhitov, R. Innate immune recognition. Annu Rev Immunol, 2002, 20, 197-216. (Pubitemid 34293424)
33. Gardai, S. J.; McPhillips, K. A.; Frasch, S. C.; Janssen, W. J.; Starefeldt, A.; Murphy-Ullrich, J. E.; Bratton, D. L.; Oldenborg, P. A.; Michalak, M.; Henson, P. M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell, 2005, 123, 321-334. (Pubitemid 41457220)
34. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J. L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 2007, 13, 54-61. (Pubitemid 46067386)
35. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol, 2007, 81, 1-5. (Pubitemid 46028489)
36. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature, 1998, 392, 245-252. (Pubitemid 28155090)
37. Bender, A.; Bui, L. K.; Feldman, M. A.; Larsson, M.; Bhardwaj, N. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med, 1995, 182, 1663-1671.
38. Schoenberger, S. P.; Toes, R. E.; van der Voort, E. I.; Offringa, R.; Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998, 393, 480-483.
39. Griffith, T. S.; Kazama, H.; Van Oosten, R. L.; Earle, J. K., Jr.; Herndon, J. M.; Green, D. R.; Ferguson, T. A. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol, 2007, 178, 2679-2687. (Pubitemid 46333144)
40. Walzer, T.; Dalod, M.; Robbins, S. H.; Zitvogel, L.; Vivier, E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood, 2005, 106, 2252-2258. (Pubitemid 41510793)
41. Lanier, L. L. NK cell recognition. Annu Rev Immunol, 2005, 23, 225-274. (Pubitemid 40563170)
42. Walzer, T.; Dalod, M.; Vivier, E.; Zitvogel, L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther, 2005, 5 Suppl 1, S49-59. (Pubitemid 41243345)
43. Chapoval, A. I.; Tamada, K.; Chen, L. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood, 2000, 95, 2346-2351. (Pubitemid 30167734)
44. Fanger, N. A.; Maliszewski, C. R.; Schooley, K.; Griffith, T. S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med, 1999, 190, 1155-1164. (Pubitemid 29496508)
45. Schmitz, M.; Zhao, S.; Deuse, Y.; Schakel, K.; Wehner, R.; Wohner, H.; Holig, K.; Wienforth, F.; Kiessling, A.; Bornhauser, M.; Temme, A.; Rieger, M. A.; Weigle, B.; Bachmann, M.; Rieber, E. P. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol, 2005, 174, 4127-4134. (Pubitemid 40395990)
46. Yang, R.; Xu, D.; Zhang, A.; Gruber, A. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumorspecific CTLs. Int J Cancer, 2001, 94, 407-413. (Pubitemid 32906073)
47. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
48. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410, 1107-1111. (Pubitemid 32391043)
49. Kaplan, D. H.; Shankaran, V.; Dighe, A. S.; Stockert, E.; Aguet, M.; Old, L. J.; Schreiber, R. D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A, 1998, 95, 7556-7561. (Pubitemid 28293291)
50. Vesely, M. D.; Kershaw, M. H.; Schreiber, R. D.; Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 2011, 29, 235-271.
51. Takahashi, R.; Nishimoto, S.; Muto, G.; Sekiya, T.; Tamiya, T.; Kimura, A.; Morita, R.; Asakawa, M.; Chinen, T.; Yoshimura, A. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production. J Exp Med, 2011, 208, 2055-2067.
52. Kamp, D. W.; Shacter, E.; Weitzman, S. A. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park), 2011, 25, 400-410, 413.
53. Bui, J. D.; Schreiber, R. D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol, 2007, 19, 203-208. (Pubitemid 46356963)
54. Demaria, S.; Pikarsky, E.; Karin, M.; Coussens, L. M.; Chen, Y. C.; El-Omar, E. M.; Trinchieri, G.; Dubinett, S. M.; Mao, J. T.; Szabo, E.; Krieg, A.; Weiner, G. J.; Fox, B. A.; Coukos, G.; Wang, E.; Abraham, R. T.; Carbone, M.; Lotze, M. T. Cancer and inflammation: promise for biologic therapy. J Immunother, 2010, 33, 335-351.
55. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454, 436-444.
56. Calderwood, S. K.; Theriault, J. R.; Gong, J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol, 2005, 35, 2518-2527. (Pubitemid 41404034)
57. Locher, C.; Rusakiewicz, S.; Tesniere, A.; Ghiringhelli, F.; Apetoh, L.; Kroemer, G.; Zitvogel, L. Witch hunt against tumor cells enhanced by dendritic cells. Ann N Y Acad Sci, 2009, 1174, 51-60.
58. Song, X.; Voronov, E.; Dvorkin, T.; Fima, E.; Cagnano, E.; Benharroch, D.; Shendler, Y.; Bjorkdahl, O.; Segal, S.; Dinarello, C. A.; Apte, R. N. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol, 2003, 171, 6448-6456. (Pubitemid 37532073)
59. Krelin, Y.; Voronov, E.; Dotan, S.; Elkabets, M.; Reich, E.; Fogel, M.; Huszar, M.; Iwakura, Y.; Segal, S.; Dinarello, C. A.; Apte, R. N. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res, 2007, 67, 1062-1071.
60. Carmi, Y.; Rinott, G.; Dotan, S.; Elkabets, M.; Rider, P.; Voronov, E.; Apte, R. N. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol, 2011, 186, 3462-3471.
61. Johnston, C. J.; Piedboeuf, B.; Rubin, P.; Williams, J. P.; Baggs, R.; Finkelstein, J. N. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res, 1996, 145, 762-767.
62. Paul, W. E. Dendritic cells bask in the limelight. Cell, 2007, 130, 967-970. (Pubitemid 47410276)
63. Kakeji, Y.; Maehara, Y.; Korenaga, D.; Tsujitani, S.; Haraguchi, M.; Watanabe, A.; Orita, H.; Sugimachi, K. Prognostic significance of tumorhost interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol, 1993, 52, 207-212. (Pubitemid 23121933)
64. Lin, A.; Schildknecht, A.; Nguyen, L. T.; Ohashi, P. S. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett, 2010, 127, 77-84.
65. Svensson, M.; Maroof, A.; Ato, M.; Kaye, P. M. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity, 2004, 21, 805-816. (Pubitemid 39626671)
66. Galluzzi, L.; Vitale, I.; Abrams, J. M.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; Dawson, T. M.; Dawson, V. L.; El-Deiry, W. S.; Fulda, S.; Gottlieb, E.; Green, D. R.; Hengartner, M. O.; Kepp, O.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Lu, X.; Madeo, F.; Malorni, W.; Mehlen, P.; Nunez, G.; Peter, M. E.; Piacentini, M.; Rubinsztein, D. C.; Shi, Y.; Simon, H. U.; Vandenabeele, P.; White, E.; Yuan, J.; Zhivotovsky, B.; Melino, G.; Kroemer, G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ, 2011.
67. Ladanyi, A.; Kiss, J.; Somlai, B.; Gilde, K.; Fejos, Z.; Mohos, A.; Gaudi, I.; Timar, J. Density of DC-LAMP (+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother, 2007, 56, 1459-1469. (Pubitemid 47024707)
68. Talmadge, J. E. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol, 2011, 21, 131-138.
69. Ladoire, S.; Martin, F.; Ghiringhelli, F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother, 2011, 60, 909-918.
70. Whiteside, T. L. Tricks tumors use to escape from immune control. Oral Oncol, 2009, 45, e119-123.
71. Lee, Y.; Auh, S. L.; Wang, Y.; Burnette, B.; Meng, Y.; Beckett, M.; Sharma, R.; Chin, R.; Tu, T.; Weichselbaum, R. R.; Fu, Y. X. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood, 2009, 114, 589-595.
72. Liu, C. C.; Perussia, B.; Cohn, Z. A.; Young, J. D. Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J Exp Med, 1986, 164, 2061-2076. (Pubitemid 17217984)
73. Ramakrishnan, R.; Assudani, D.; Nagaraj, S.; Hunter, T.; Cho, H. I.; Antonia, S.; Altiok, S.; Celis, E.; Gabrilovich, D. I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest, 2010, 120, 1111-1124.
74. Correale, P.; Del Vecchio, M. T.; La Placa, M.; Montagnani, F.; Di Genova, G.; Savellini, G. G.; Terrosi, C.; Mannucci, S.; Giorgi, G.; Francini, G.; Cusi, M. G. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother, 2008, 31, 132-147.
75. Ma, Y.; Conforti, R.; Aymeric, L.; Locher, C.; Kepp, O.; Kroemer, G.; Zitvogel, L. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev, 2011, 30, 71-82.
76. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Criollo, A.; Ortiz, C.; Lidereau, R.; Mariette, C.; Chaput, N.; Mira, J. P.; Delaloge, S.; Andre, F.; Tursz, T.; Kroemer, G.; Zitvogel, L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev, 2007, 220, 47-59. (Pubitemid 350045573)
77. Accapezzato, D.; Visco, V.; Francavilla, V.; Molette, C.; Donato, T.; Paroli, M.; Mondelli, M. U.; Doria, M.; Torrisi, M. R.; Barnaba, V. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med, 2005, 202, 817-828. (Pubitemid 41345970)
78. Chamoto, K.; Wakita, D.; Narita, Y.; Zhang, Y.; Noguchi, D.; Ohnishi, H.; Iguchi, T.; Sakai, T.; Ikeda, H.; Nishimura, T. An essential role of antigenpresenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res, 2006, 66, 1809-1817. (Pubitemid 43259967)
79. Leong, S. P.; Zuber, M.; Ferris, R. L.; Kitagawa, Y.; Cabanas, R.; Levenback, C.; Faries, M.; Saha, S. Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. J Surg Oncol, 2011, 103, 518-530.
80. Burnette, B. C.; Liang, H.; Lee, Y.; Chlewicki, L.; Khodarev, N. N.; Weichselbaum, R. R.; Fu, Y. X.; Auh, S. L. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res, 2011, 71, 2488-2496.
81. Lugade, A. A.; Sorensen, E. W.; Gerber, S. A.; Moran, J. P.; Frelinger, J. G.; Lord, E. M. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol, 2008, 180, 3132-3139.
82. Dunn, G. P.; Koebel, C. M.; Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol, 2006, 6, 836-848. (Pubitemid 44631652)
83. Gao, Y.; Yang, W.; Pan, M.; Scully, E.; Girardi, M.; Augenlicht, L. H.; Craft, J.; Yin, Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med, 2003, 198, 433-442. (Pubitemid 36976054)
84. Colombo, M. P.; Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 2002, 13, 155-168. (Pubitemid 34229390)
85. Swann, J. B.; Hayakawa, Y.; Zerafa, N.; Sheehan, K. C.; Scott, B.; Schreiber, R. D.; Hertzog, P.; Smyth, M. J. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol, 2007, 178, 7540-7549. (Pubitemid 46898022)
86. Fuertes, M. B.; Kacha, A. K.; Kline, J.; Woo, S.-R.; Kranz, D. M.; Murphy, K. M.; Gajewski, T. F. Host type I IFN signals are reuired for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med, 2011, 208, 2005-2016.
87. Apetoh, L.; Vegran, F.; Ladoire, S.; Ghiringhelli, F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med, 2011, 11, 365-372.
88. Morak, M. J.; van Koetsveld, P. M.; Kanaar, R.; Hofland, L. J.; van Eijck, C. H. Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer, 2011, 47, 1938-1945.
89. McBride, W. H.; Chiang, C. S.; Olson, J. L.; Wang, C. C.; Hong, J. H.; Pajonk, F.; Dougherty, G. J.; Iwamoto, K. S.; Pervan, M.; Liao, Y. P. A sense of danger from radiation. Radiat Res, 2004, 162, 1-19. (Pubitemid 39044714)
90. Chakraborty, M.; Abrams, S. I.; Coleman, C. N.; Camphausen, K.; Schlom, J.; Hodge, J. W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res, 2004, 64, 4328-4337. (Pubitemid 38802440)
91. Liao, Y. P.; Wang, C. C.; Butterfield, L. H.; Economou, J. S.; Ribas, A.; Meng, W. S.; Iwamoto, K. S.; McBride, W. H. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol, 2004, 173, 2462-2469. (Pubitemid 39063103)
92. Reits, E. A.; Hodge, J. W.; Herberts, C. A.; Groothuis, T. A.; Chakraborty, M.; Wansley, E. K.; Camphausen, K.; Luiten, R. M.; de Ru, A. H.; Neijssen, J.; Griekspoor, A.; Mesman, E.; Verreck, F. A.; Spits, H.; Schlom, J.; van Veelen, P.; Neefjes, J. J. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med, 2006, 203, 1259-1271. (Pubitemid 43736595)
93. Finn, O. J. Cancer immunology. N Engl J Med, 2008, 358, 2704-2715.
94. Eriksson, D.; Stigbrand, T. Radiation-induced cell death mechanisms. Tumour Biol, 2010, 31, 363-372.
95. Gaipl, U. S.; Sheriff, A.; Franz, S.; Munoz, L. E.; Voll, R. E.; Kalden, J. R.; Herrmann, M. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol, 2006, 305, 161-176. (Pubitemid 47400269)
96. Frey, B.; Gaipl, U. S. The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. Semin Immunopathol, 2011, 33, 497-516.
97. Voll, R. E.; Herrmann, M.; Roth, E. A.; Stach, C.; Kalden, J. R.; Girkontaite, I. Immunosuppressive effects of apoptotic cells. Nature, 1997, 390, 350-351.
98. Gregory, C. D.; Pound, J. D. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol, 2011, 223, 177-194.
99. Chen, X.; Doffek, K.; Sugg, S. L.; Shilyansky, J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol, 2004, 173, 2985-2994. (Pubitemid 39142003)
100. Doffek, K.; Chen, X.; Sugg, S. L.; Shilyansky, J. Phosphatidylserine inhibits NFkappaB and p38 MAPK activation in human monocyte derived dendritic cells. Mol Immunol, 2011, 48, 1771-1777.
101. Danna, E. A.; Sinha, P.; Gilbert, M.; Clements, V. K.; Pulaski, B. A.; Ostrand-Rosenberg, S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res, 2004, 64, 2205-2211. (Pubitemid 38339474)
102. Campana, L.; Bosurgi, L.; Rovere-Querini, P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol, 2008, 20, 518-523.
103. Shen, X.; Hong, L.; Sun, H.; Shi, M.; Song, Y. The expression of highmobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep, 2009, 22, 535-539.
104. Zitvogel, L.; Kepp, O.; Kroemer, G. Decoding cell death signals in inflammation and immunity. Cell, 2010, 140, 798-804.
105. Hitomi, J.; Christofferson, D. E.; Ng, A.; Yao, J.; Degterev, A.; Xavier, R. J.; Yuan, J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell, 2008, 135, 1311-1323.
106. Gunther, C.; Martini, E.; Wittkopf, N.; Amann, K.; Weigmann, B.; Neumann, H.; Waldner, M. J.; Hedrick, S. M.; Tenzer, S.; Neurath, M. F.; Becker, C. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature, 2011, 477, 335-339.
107. Degterev, A.; Hitomi, J.; Germscheid, M.; Ch'en, I. L.; Korkina, O.; Teng, X.; Abbott, D.; Cuny, G. D.; Yuan, C.; Wagner, G.; Hedrick, S. M.; Gerber, S. A.; Lugovskoy, A.; Yuan, J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol, 2008, 4, 313-321. (Pubitemid 351550892)
108. Cho, Y.; McQuade, T.; Zhang, H.; Zhang, J.; Chan, F. K. RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation. PLoS One, 2011, 6, e23209.
109. Green, D. R.; Ferguson, T.; Zitvogel, L.; Kroemer, G. Immunogenic and tolerogenic cell death. Nat Rev Immunol, 2009, 9, 353-363.
110. Caruso, R.; Fedele, F.; Luciano, R.; Branca, G.; Parisi, C.; Paparo, D.; Parisi, A. Mitotic catastrophe in malignant epithelial tumors: the pathologist's viewpoint. Ultrastruct Pathol, 2011, 35, 66-71.
111. Schildkopf, P.; Holmer, R.; Sieber, R.; Ott, O. J.; Janko, C.; Mantel, F.; Frey, B.; Fietkau, R.; Gaipl, U. S. Hyperthermia in combination with X-irradiation induces inflammatory forms of cell death. Autoimmunity, 2009, 42, 311-313.
112. Munoz, L. E.; Frey, B.; Pausch, F.; Baum, W.; Mueller, R. B.; Brachvogel, B.; Poschl, E.; Rodel, F.; von der Mark, K.; Herrmann, M.; Gaipl, U. S. The role of annexin A5 in the modulation of the immune response against dying and dead cells. Curr Med Chem, 2007, 14, 271-277.
113. Garg, A. D.; Nowis, D.; Golab, J.; Vandenabeele, P.; Krysko, D. V.; Agostinis, P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta, 2010, 1805, 53-71.
114. Gaipl, U. S.; Kuenkele, S.; Voll, R. E.; Beyer, T. D.; Kolowos, W.; Heyder, P.; Kalden, J. R.; Herrmann, M. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ, 2001, 8, 327-334. (Pubitemid 32409603)
115. Silva, M. T. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett, 2010, 584, 4491-4499.
116. Poon, I. K.; Hulett, M. D.; Parish, C. R. Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ, 2010, 17, 381-397.
117. Frey, B.; Schildkopf, P.; Rodel, F.; Weiss, E. M.; Munoz, L. E.; Herrmann, M.; Fietkau, R.; Gaipl, U. S. AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J Immunotoxicol, 2009, 6, 209-216.
118. Hoves, S.; Sutton, V. R.; Haynes, N. M.; Hawkins, E. D.; Fernandez Ruiz, D.; Baschuk, N.; Sedelies, K. A.; Schnurr, M.; Stagg, J.; Andrews, D. M.; Villadangos, J. A.; Trapani, J. A. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J Immunol, 2011, 187, 1166-1175.
119. Bondanza, A.; Zimmermann, V. S.; Rovere-Querini, P.; Turnay, J.; Dumitriu, I. E.; Stach, C. M.; Voll, R. E.; Gaipl, U. S.; Bertling, W.; Poschl, E.; Kalden, J. R.; Manfredi, A. A.; Herrmann, M. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med, 2004, 200, 1157-1165. (Pubitemid 39507055)
120. Rosenbaum, S.; Kreft, S.; Etich, J.; Frie, C.; Stermann, J.; Grskovic, I.; Frey, B.; Mielenz, D.; Poschl, E.; Gaipl, U.; Paulsson, M.; Brachvogel, B. Identification of novel binding partners (annexins) for the cell death signal phosphatidylserine and definition of their recognition motif. J Biol Chem, 2011, 286, 5708-5716.
121. Horisberger, K.; Erben, P.; Strobel, P.; Bohn, B.; Hahn, M.; Kahler, G.; Wenz, F.; Hochhaus, A.; Post, S.; Willeke, F.; Hofheinz, R. D. Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy? Onkologie, 2010, 33, 439-444.
122. Boyajyan, A. S.; Mkrtchyan, G. M.; Hovhannisyan, L. P.; Hovsepyan, T. J. Increased levels of circulating Annexin A5 in Familial Mediterranean fever. J Inflamm (Lond), 2010, 7, 55.
123. Gaipl, U. S.; Munoz, L. E.; Rodel, F.; Pausch, F.; Frey, B.; Brachvogel, B.; von der Mark, K.; Poschl, E. Modulation of the immune system by dying cells and the phosphatidylserine-ligand annexin A5. Autoimmunity, 2007, 40, 254-259. (Pubitemid 46845517)
124. Ran, S.; Downes, A.; Thorpe, P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res, 2002, 62, 6132-6140. (Pubitemid 35244462)
125. Huang, X.; Ye, D.; Thorpe, P. E. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine, 2011, 29, 4785-4793.
126. He, J.; Yin, Y.; Luster, T. A.; Watkins, L.; Thorpe, P. E. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res, 2009, 15, 6871-6880.
127. Derose, P.; Thorpe, P. E.; Gerber, D. E. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy, 2011, 3, 933-944.
128. Ran, S.; He, J.; Huang, X.; Soares, M.; Scothorn, D.; Thorpe, P. E. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res, 2005, 11, 1551-1562. (Pubitemid 40315240)
129. Krieg, C.; Letourneau, S.; Pantaleo, G.; Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A, 2010, 107, 11906-11911.
130. Huang, X.; Bennett, M.; Thorpe, P. E. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res, 2005, 65, 4408-4416. (Pubitemid 40775680)
131. Kenis, H.; van Genderen, H.; Bennaghmouch, A.; Rinia, H. A.; Frederik, P.; Narula, J.; Hofstra, L.; Reutelingsperger, C. P. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem, 2004, 279, 52623-52629. (Pubitemid 39656638)
132. Kenis, H.; Reutelingsperger, C. Targeting phosphatidylserine in anti-cancer therapy. Curr Pharm Des, 2009, 15, 2719-2723.
133. Gehrmann, M.; Schilling, D.; Molls, M.; Multhoff, G. Radiation induced stress proteins. Int J Clin Pharmacol Ther, 2010, 48, 492-493.
134. Riedl, S.; Rinner, B.; Asslaber, M.; Schaider, H.; Walzer, S.; Novak, A.; Lohner, K.; Zweytick, D. In search of a novel target - Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta, 2011, 1808, 2638-2645.
135. Casares, N.; Pequignot, M. O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Metivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 2005, 202, 1691-1701. (Pubitemid 41815875)
136. Basu, S.; Binder, R. J.; Ramalingam, T.; Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 2001, 14, 303-313. (Pubitemid 32289294)
137. Vandivier, R. W.; Ogden, C. A.; Fadok, V. A.; Hoffmann, P. R.; Brown, K. K.; Botto, M.; Walport, M. J.; Fisher, J. H.; Henson, P. M.; Greene, K. E. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol, 2002, 169, 3978-3986.
138. Martins, I.; Kepp, O.; Galluzzi, L.; Senovilla, L.; Schlemmer, F.; Adjemian, S.; Menger, L.; Michaud, M.; Zitvogel, L.; Kroemer, G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci, 2010, 1209, 77-82.
139. Aguilera, R.; Saffie, C.; Tittarelli, A.; Gonzalez, F. E.; Ramirez, M.; Reyes, D.; Pereda, C.; Hevia, D.; Garcia, T.; Salazar, L.; Ferreira, A.; Hermoso, M.; Mendoza-Naranjo, A.; Ferrada, C.; Garrido, P.; Lopez, M. N.; Salazar-Onfray, F. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res, 2011, 17, 2474-2483.
140. Schnurr, M.; Then, F.; Galambos, P.; Scholz, C.; Siegmund, B.; Endres, S.; Eigler, A. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol, 2000, 165, 4704-4709.
141. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; Perfettini, J. L.; Schlemmer, F.; Tasdemir, E.; Uhl, M.; Genin, P.; Civas, A.; Ryffel, B.; Kanellopoulos, J.; Tschopp, J.; Andre, F.; Lidereau, R.; McLaughlin, N. M.; Haynes, N. M.; Smyth, M. J.; Kroemer, G.; Zitvogel, L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med, 2009, 15, 1170-1178.
142. Mariathasan, S.; Weiss, D. S.; Newton, K.; McBride, J.; O'Rourke, K.; Roose-Girma, M.; Lee, W. P.; Weinrauch, Y.; Monack, D. M.; Dixit, V. M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature, 2006, 440, 228-232. (Pubitemid 43372102)
143. Li, H.; Ambade, A.; Re, F. Cutting edge: Necrosis activates the NLRP3 inflammasome. J Immunol, 2009, 183, 1528-1532.
144. Elliott, M. R.; Chekeni, F. B.; Trampont, P. C.; Lazarowski, E. R.; Kadl, A.; Walk, S. F.; Park, D.; Woodson, R. I.; Ostankovich, M.; Sharma, P.; Lysiak, J. J.; Harden, T. K.; Leitinger, N.; Ravichandran, K. S. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 2009, 461, 282-286.
145. Schmitt, E.; Parcellier, A.; Ghiringhelli, F.; Casares, N.; Gurbuxani, S.; Droin, N.; Hamai, A.; Pequignot, M.; Hammann, A.; Moutet, M.; Fromentin, A.; Kroemer, G.; Solary, E.; Garrido, C. Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res, 2004, 64, 2705-2711. (Pubitemid 38500605)
146. Scaffidi, P.; Misteli, T.; Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418, 191-195. (Pubitemid 34773774)
147. Sauter, B.; Albert, M. L.; Francisco, L.; Larsson, M.; Somersan, S.; Bhardwaj, N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med, 2000, 191, 423-434.
148. Dumitriu, I. E.; Bianchi, M. E.; Bacci, M.; Manfredi, A. A.; Rovere-Querini, P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol, 2007, 81, 84-91. (Pubitemid 46021256)
149. Curtin, J. F.; Liu, N.; Candolfi, M.; Xiong, W.; Assi, H.; Yagiz, K.; Edwards, M. R.; Michelsen, K. S.; Kroeger, K. M.; Liu, C.; Muhammad, A. K.; Clark, M. C.; Arditi, M.; Comin-Anduix, B.; Ribas, A.; Lowenstein, P. R.; Castro, M. G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med, 2009, 6, e10.
150. Candolfi, M.; Yagiz, K.; Foulad, D.; Alzadeh, G. E.; Tesarfreund, M.; Muhammad, A. K.; Puntel, M.; Kroeger, K. M.; Liu, C.; Lee, S.; Curtin, J. F.; King, G. D.; Lerner, J.; Sato, K.; Mineharu, Y.; Xiong, W.; Lowenstein, P. R.; Castro, M. G. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res, 2009, 15, 4401-4414.
151. Tang, D.; Kang, R.; Zeh, H. J., 3rd; Lotze, M. T. High-mobility group box 1 and cancer. Biochim Biophys Acta, 2010, 1799, 131-140.
152. Chen, T.; Guo, J.; Han, C.; Yang, M.; Cao, X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol, 2009, 182, 1449-1459.
153. Somersan, S.; Larsson, M.; Fonteneau, J. F.; Basu, S.; Srivastava, P.; Bhardwaj, N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol, 2001, 167, 4844-4852. (Pubitemid 33009712)
154. Wang, Y.; Kelly, C. G.; Singh, M.; McGowan, E. G.; Carrara, A. S.; Bergmeier, L. A.; Lehner, T. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol, 2002, 169, 2422-2429. (Pubitemid 34920985)
155. Schildkopf, P.; Frey, B.; Ott, O. J.; Rubner, Y.; Multhoff, G.; Sauer, R.; Fietkau, R.; Gaipl, U. S. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of proinflammatory cytokines by dendritic cells and macrophages. Radiother Oncol, 2011, 101, 109-115.
156. Binder, R. J.; Blachere, N. E.; Srivastava, P. K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem, 2001, 276, 17163-17171.
157. Udono, H.; Srivastava, P. K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med, 1993, 178, 1391-1396. (Pubitemid 23277370)
158. Udono, H.; Levey, D. L.; Srivastava, P. K. Cellular requirements for tumorspecific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A, 1994, 91, 3077-3081. (Pubitemid 24130178)
159. Basu, S.; Srivastava, P. K. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor-and peptide-specific immunity. J Exp Med, 1999, 189, 797-802. (Pubitemid 29189684)
160. Wang, X. Y.; Kazim, L.; Repasky, E. A.; Subjeck, J. R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol, 2001, 166, 490-497. (Pubitemid 32038468)
161. Arnold-Schild, D.; Hanau, D.; Spehner, D.; Schmid, C.; Rammensee, H. G.; de la Salle, H.; Schild, H. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol, 1999, 162, 3757-3760. (Pubitemid 29314749)
162. Singh-Jasuja, H.; Hilf, N.; Arnold-Schild, D.; Schild, H. The role of heat shock proteins and their receptors in the activation of the immune system. Biol Chem, 2001, 382, 629-636. (Pubitemid 32472173)
163. Basu, S.; Binder, R. J.; Suto, R.; Anderson, K. M.; Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol, 2000, 12, 1539-1546.
164. Vega, V. L.; Rodriguez-Silva, M.; Frey, T.; Gehrmann, M.; Diaz, J. C.; Steinem, C.; Multhoff, G.; Arispe, N.; De Maio, A. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol, 2008, 180, 4299-4307.
165. Pisetsky, D. S.; Gauley, J.; Ullal, A. J. HMGB1 and Microparticles as Mediators of the Immune Response to Cell Death. Antioxid Redox Signal, 2011, 15, 2209-2219.
166. Gehrmann, M.; Liebisch, G.; Schmitz, G.; Anderson, R.; Steinem, C.; De Maio, A.; Pockley, G.; Multhoff, G. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One, 2008, 3, e1925.
167. Schmid, T. E.; Multhoff, G. Radiation-induced stress proteins - the role of Heat Shock Proteins (HSP) in anti-tumor responses. Curr Med Chem, 2012, 19(12), 1765-1770.
168. Jiang, W.; Li, J.; Gallowitsch-Puerta, M.; Tracey, K. J.; Pisetsky, D. S. The effects of CpG DNA on HMGB1 release by murine macrophage cell lines. J Leukoc Biol, 2005, 78, 930-936. (Pubitemid 41384409)
169. Jiang, W.; Pisetsky, D. S. The induction of HMGB1 release from RAW 264.7 cells by transfected DNA. Mol Immunol, 2008, 45, 2038-2044. (Pubitemid 351226268)
170. Tang, D.; Shi, Y.; Kang, R.; Li, T.; Xiao, W.; Wang, H.; Xiao, X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol, 2007, 81, 741-747. (Pubitemid 46393551)
171. Ehrchen, J. M.; Sunderkotter, C.; Foell, D.; Vogl, T.; Roth, J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol, 2009, 86, 557-566.
172. Shi, Y.; Evans, J. E.; Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003, 425, 516-521. (Pubitemid 37237047)
173. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440, 237-241. (Pubitemid 43372104)
174. Terme, M.; Ullrich, E.; Aymeric, L.; Meinhardt, K.; Desbois, M.; Delahaye, N.; Viaud, S.; Ryffel, B.; Yagita, H.; Kaplanski, G.; Prevost-Blondel, A.; Kato, M.; Schultze, J. L.; Tartour, E.; Kroemer, G.; Chaput, N.; Zitvogel, L. IL-18 Induces PD-1-Dependent Immunosuppression in Cancer. Cancer Res, 2011, 71, 5393-5399.
175. Schorn, C.; Frey, B.; Lauber, K.; Janko, C.; Strysio, M.; Keppeler, H.; Gaipl, U. S.; Voll, R. E.; Springer, E.; Munoz, L. E.; Schett, G.; Herrmann, M. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem, 2011, 286, 35-41.
176. Tewary, P.; Yang, D.; de la Rosa, G.; Li, Y.; Finn, M. W.; Krensky, A. M.; Clayberger, C.; Oppenheim, J. J. Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. Blood, 2010, 116, 3465-3474.
177. Babelova, A.; Moreth, K.; Tsalastra-Greul, W.; Zeng-Brouwers, J.; Eickelberg, O.; Young, M. F.; Bruckner, P.; Pfeilschifter, J.; Schaefer, R. M.; Grone, H. J.; Schaefer, L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem, 2009, 284, 24035-24048.
178. Zeiser, R.; Penack, O.; Holler, E.; Idzko, M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl), 2011, 89, 833-845.
179. Soiffer, R.; Hodi, F. S.; Haluska, F.; Jung, K.; Gillessen, S.; Singer, S.; Tanabe, K.; Duda, R.; Mentzer, S.; Jaklitsch, M.; Bueno, R.; Clift, S.; Hardy, S.; Neuberg, D.; Mulligan, R.; Webb, I.; Mihm, M.; Dranoff, G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol, 2003, 21, 3343-3350. (Pubitemid 46606268)
180. Machiels, J. P.; Reilly, R. T.; Emens, L. A.; Ercolini, A. M.; Lei, R. Y.; Weintraub, D.; Okoye, F. I.; Jaffee, E. M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res, 2001, 61, 3689-3697. (Pubitemid 32694981)
181. Sittler, T.; Zhou, J.; Park, J.; Yuen, N. K.; Sarantopoulos, S.; Mollick, J.; Salgia, R.; Giobbie-Hurder, A.; Dranoff, G.; Hodi, F. S. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res, 2008, 14, 3896-3905.
182. Chamoto, K.; Takeshima, T.; Wakita, D.; Ohkuri, T.; Ashino, S.; Omatsu, T.; Shirato, H.; Kitamura, H.; Togashi, Y.; Nishimura, T. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio-and immuno-resistant lung carcinoma cells. Cancer Sci, 2009, 100, 934-939.
183. Nierkens, S.; den Brok, M. H.; Garcia, Z.; Togher, S.; Wagenaars, J.; Wassink, M.; Boon, L.; Ruers, T. J.; Figdor, C. G.; Schoenberger, S. P.; Adema, G. J.; Janssen, E. M. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res, 2011, 71, 6428-6437.
184. Liao, Y. P.; Wang, C. C.; Schaue, D.; Iwamoto, K. S.; McBride, W. H. Local irradiation of murine melanoma affects the development of tumour-specific immunity. Immunology, 2009, 128, e797-804.
185. Schaue, D.; Comin-Anduix, B.; Ribas, A.; Zhang, L.; Goodglick, L.; Sayre, J. W.; Debucquoy, A.; Haustermans, K.; McBride, W. H. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res, 2008, 14, 4883-4890.
186. Antonia, S. J.; Mirza, N.; Fricke, I.; Chiappori, A.; Thompson, P.; Williams, N.; Bepler, G.; Simon, G.; Janssen, W.; Lee, J. H.; Menander, K.; Chada, S.; Gabrilovich, D. I. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 2006, 12, 878-887. (Pubitemid 43259871)
187. Arlen, P. M.; Gulley, J. L.; Parker, C.; Skarupa, L.; Pazdur, M.; Panicali, D.; Beetham, P.; Tsang, K. Y.; Grosenbach, D. W.; Feldman, J.; Steinberg, S. M.; Jones, E.; Chen, C.; Marte, J.; Schlom, J.; Dahut, W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res, 2006, 12, 1260-1269. (Pubitemid 43342517)
188. Wheeler, C. J.; Das, A.; Liu, G.; Yu, J. S.; Black, K. L. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res, 2004, 10, 5316-5326. (Pubitemid 39100466)
189. Wheeler, C. J.; Black, K. L.; Liu, G.; Mazer, M.; Zhang, X. X.; Pepkowitz, S.; Goldfinger, D.; Ng, H.; Irvin, D.; Yu, J. S. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res, 2008, 68, 5955-5964.
190. Perez, C. A.; Fu, A.; Onishko, H.; Hallahan, D. E.; Geng, L. Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol, 2009, 85, 1126-1136.
191. Kato, N.; Tanaka, J.; Sugita, J.; Toubai, T.; Miura, Y.; Ibata, M.; Syono, Y.; Ota, S.; Kondo, T.; Asaka, M.; Imamura, M. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia, 2007, 21, 2103-2108. (Pubitemid 47423800)
192. Kavanagh, B. D.; Miften, M.; Rabinovitch, R. A. Advances in treatment techniques: stereotactic body radiation therapy and the spread of hypofractionation. Cancer J, 2011, 17, 177-181.
193. Firat, E.; Heinemann, F.; Grosu, A. L.; Hermann, F.; Niedermann, G. Molecular radiobiology meets clinical radiation oncology. Int J Radiat Biol, 2010, 86, 252-259.
194. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Andre, F.; Tesniere, A.; Kroemer, G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest, 2008, 118, 1991-2001. (Pubitemid 351872317)
195. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998, 282, 2085-2088. (Pubitemid 29001265)
196. Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J. M.; Hoffmann, J. A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 1996, 86, 973-983. (Pubitemid 26336801)
197. Steinman, R. M.; Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med, 1973, 137, 1142-1162.
198. Galluzzi, L.; Vitale, I.; Kroemer, G. Past, present, and future of molecular and cellular oncology. Frontiers in Molecular and Cellular Oncology, 2011.
199. Fridman, W. H.; Galon, J.; Pages, F.; Tartour, E.; Sautes-Fridman, C.; Kroemer, G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res, 2011, 71, 5601-5605.